At the last check on Friday, Xeris Biopharma Holdings Inc.’s (NASDAQ:XERS) stock was up $0.18, moving up 8.53 percent to $2.30. The average number of shares traded per day over the past five days has been 1,008,971 shares. 1 time new highs have been achieved over the past 5 days, with a $0.02 gain in that time frame. In the last twenty days, the average volume was 1,018,303, while in the previous 50 days, it was 1,122,579.
Since last month, XERS stock retreated -10.82%. Shares of the company fell to $2.09 on 08/18/23, the lowest level in the past month. A 52-week high of $3.07 was reached on 06/21/23 after having rallying from a 52-week low of $0.97. Since the beginning of this year, XERS’s stock price has risen by 73.00% or $0.97 and marked a new high 23 times. However, the stock has declined by -25.05% since its 52-week high.
XERS stock investors should be aware that Xeris Biopharma Holdings Inc. (XERS) stock had its last reported insider trading activity 9 days ago on Aug 09. Edick Paul R purchased of 10,000 shares for $2.38 on Aug 09. It resulted in a $23,794 investment by the insider. Edick Paul R added 20,000 shares at an average price of $1.45 on Dec 13. The insider now owns 1,528,064 shares following the transaction.
Valuation Metrics
The stock’s beta is 1.31. Besides these, the trailing price-to-sales (P/S) ratio of 2.41, the price-to-book (PB) ratio of 23.01.
Financial Health
In the three months ended June 29, Xeris Biopharma Holdings Inc.’s quick ratio stood at 1.50, while its current ratio was 2.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 13.84, and the total debt-to-equity ratio was 13.84. On the profitability front, the trailing twelve-month gross margin is 81.80% percent. In the year ended June 29, EBITDA margin amounted to -61.48%, whereas operating margins totaled -47.20%. Based on annual data, XERS earned $87.61 million in gross profit and brought in $110.25 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -35.20%. Return on equity (ROE) for the past 12 months was -198.60%.
In Xeris Biopharma Holdings Inc.’s quarter-end financial report for June 29, it reported total debt of $188.18 million against cash and short-term investments of $34.5 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. XERS’s revenue rose 41.94% to $33.14 million during the quarter, while net income inched up to $38.01 million. While analysts expected Xeris Biopharma Holdings Inc. to report -$0.13 quarterly earnings, the actual figure was -$0.14 per share, beating the consensus estimate by -7.70%. During the quarter, the company generated -$13.7 million in EBITDA. The liabilities of Xeris Biopharma Holdings Inc. were 315.14 million at the end of its most recent quarter ended June 29, and its total debt was $224.99 million. The value of shareholders’ equity is $138.07 million.
Technical Picture
This quick technical analysis looks at Xeris Biopharma Holdings Inc.’s (XERS) price momentum. With a historical volatility rate of 70.64%, the RSI 9-day stood at 44.90% on 17 August.
With respect to its five-day moving average, the current Xeris Biopharma Holdings Inc. price is up by +0.88% percent or $0.02. At present, XERS shares trade -9.80% below its 20-day simple moving average and +81.10% percent above its 100-day simple moving average. However, the stock is currently trading approximately -20.69% below its SMA50 and +43.75% above its SMA200.
Stochastic coefficient K was 12.69% and Stochastic coefficient D was 11.23%, while ATR was 0.17. Given the Stochastic reading of 30.43% for the 14-day period, the RSI (14) reading has been calculated as 44.12%. As of today, the MACD Oscillator reading stands at -0.09, while the 14-day reading stands at -0.21.
Analyst Ratings
Jefferies launched its rating on Xeris Biopharma Holdings Inc. (NASDAQ: XERS) to a Buy in a note to investors on October 21, 2022. Xeris Biopharma Holdings Inc. (XERS) has been rated Buy by analysts. According to 0 brokerage firms, XERS is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Xeris Biopharma Holdings Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $5.00, the current consensus forecast for the stock is $4.00 – $6.00. Based on these forecasts, analysts predict Xeris Biopharma Holdings Inc. (XERS) will achieve an average price target of $5.00.
